Conference Coverage

VIDEO: Study of hs-cTnT in chest pain intriguing, but flawed


 

AT ACC 14

WASHINGTON – The lack of detectable high-sensitivity cardiac troponin T in patients presenting with chest pain may be a marker of minimal risk of myocardial infarction within 30 days, according to Dr. Nadia Bandstein of the department of medicine at the Karolinska Institute, Solna, Sweden.

She and her colleagues looked at data from all emergency department visits for chest pain during 2010-2012 in Sweden. They found that the negative predictive value of myocardial infarction at 30 days for patients reporting with an hs-cTnT level of less than 5 ng/L, in addition to an ECG showing no blood flow-related damage, was 99.8%. That negative predictive value for death, meaning the patients are not at risk, was 100%.

Discussant Dr. Allan Jaffe of the Mayo Clinic in Rochester, Minn., said in an interview that although these findings are promising, the documentation in this study is not sufficient to use in clinical practice to let patients with these characteristics leave the emergency department.

*Update (3/31/14): This video has been updated.

mzoler@frontlinemedcom.com

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Studies question benefits of induced hypothermia after cardiac arrest
MDedge Emergency Medicine
Noninvasive coronary test accurate for lesion-specific ischemia
MDedge Emergency Medicine
Chest pain traits didn’t identify MI in women
MDedge Emergency Medicine
Work cardiac resuscitations in the field, not the ambulance
MDedge Emergency Medicine
Mechanical device as effective as manual chest compressions
MDedge Emergency Medicine
FDA panel rejects rivaroxaban again for acute coronary syndrome
MDedge Emergency Medicine
FDA reviewers support approval of platelet inhibitor cangrelor for PCI indication
MDedge Emergency Medicine
FDA panel votes against cangrelor approval for PCI, bridge indications
MDedge Emergency Medicine
No ACS approvals for rivaroxaban, Janssen announces
MDedge Emergency Medicine
RAS blocker prescriptions still lag for ACS patients
MDedge Emergency Medicine